Funded in part by Pfizer, Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológic
Anti-CD44-Conjugated Olive Oil Liquid Nanocapsules for Targeting Pancreatic Cancer Stem Cells
Navarro-Marchal SA, Griñán-Lisón C, Entrena JM, Ruiz-Alcalá G, Tristán-Manzano M, Martin F, Pérez-Victoria I, Peula-García JM, Marchal JA
Biomacromolecules · 30 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- In vitro/mechanistic study (classified by our AI screen)
- Studied in
- People, plus animal or lab work
- Main outcome
- Clinical events such as disease or death
Who paid for it
- Funding
- Industry funded
- Company
- Pfizer
- Government
- Ministerio de Ciencia, Innovación y Universidades
- Government
- European Commission
- Government
- Ministerio de Economía y Competitividad
- Government
- Ministerio de Ciencia e Innovación
- University or hospital
- Centre d'Imagerie BioMédicale
- University or hospital
- Universidad de Granada
- Company
- Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológic
- Nonprofit
- Fundación MEDINA
- Government
- Junta de Andalucía
- Government
- Instituto de Salud Carlos III
- Government
- European Regional Development Fund
- Government
- Ministerio de Econom?a y Competitividad
- Government
- Ministerio de Ciencia, Innovaci?n y Universidades
- Government
- Ministerio de Ciencia e Innovaci?n
- Government
- Consejer?a de Econom?a, Conocimiento, Empresas y Universidad de la Junta de Andaluc?a
- Government
- Consejer?a de Salud de la Junta de Andaluc?a
- Grants
- European Regional Development Fund (PI18/00337); Ministerio de Ciencia e Innovación (RTI2018-101309-B-C21); Ministerio de Ciencia, Innovación y Universidades (RTI2018.101309B-C21); European Regional Development Fund (SOMM17/6109/UGR.); Ministerio de Ciencia e Innovación (PCT- 010000-2010-4); Instituto de Salud Carlos III (PI15/02015); Instituto de Salud Carlos III (RTI2018-101309-B-C22); European Regional Development Fund (RTI2018-101309-B-C21); European Regional Development Fund (PI15/02015); Ministerio de Economía y Competitividad (MAT2015-63644-C2-2-R); European Regional Development Fund (RTI2018); Ministerio de Economía y Competitividad (FPU16/05467); Ministerio de Ciencia e Innovación (RTI2018.101309B-C22); Ministerio de Ciencia e Innovación (PI15/); Ministerio de Economía y Competitividad (PCT-010000-2010-4); European Regional Development Fund (MAT2015-63644-C2-1-R); Ministerio de Ciencia e Innovación (PI15/02015); Instituto de Salud Carlos III (PI18/00337); Ministerio de Ciencia, Innovación y Universidades (PCT-010000-2010-4); Ministerio de Ciencia, Innovación y Universidades (RTI2018); Ministerio de Economía y Competitividad (MAT2015-63644-C2-1-R); Ministerio de Ciencia, Innovación y Universidades (RTI2018-101309-B-C22)
Based on 17 listed funder(s).
Publication
- Published
- 2021-03-16 · Biomacromolecules · vol. 22 · issue 4 · pp. 1374–1388
- Publisher
- American Chemical Society
- Cited
- 49 citations · more than 83% of similar papers · 1.7× the field average
- References
- 76 works
- Access
- Open access (hybrid journal) · CC-BY-NC-ND
- Research areas
- Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics
- Keywords
- Nanocarriers, Chemistry, CD44, In vivo, Cancer stem cell, Nanocapsules, Drug delivery, Stem cell, In vitro, Materials science, Biochemistry, Nanotechnology, Nanoparticle, Cell biology, Organic chemistry, Biology, Biotechnology
- MeSH
- humans, pancreatic neoplasms, paclitaxel, nanocapsules, neoplastic stem cells, olive oil
9 authors
From ES
- Saúl A. Navarro-MarchalUniversidad de Granada; Instituto de Investigación Biosanitaria de Granada
- Carmen Griñán‐LisónUniversidad de Granada; Instituto de Investigación Biosanitaria de Granada
- José-Manuel EntrenaUniversidad de Granada; Parque Tecnológico de la Salud
- Gloria Ruiz-AlcaláUniversidad de Granada; Instituto de Investigación Biosanitaria de Granada
- María Tristán‐ManzanoPfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research
- Francisco Martı́nPfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research
Abstract
The latest trends in cancer research and nanomedicine focus on using nanocarriers to target cancer stem cells (CSCs). Specifically, lipid liquid nanocapsules are usually developed as nanocarriers for lipophilic drug delivery. Here, we developed olive oil liquid NCs (O2LNCs) functionalized by covalent coupling of an anti-CD44-fluorescein isothiocyanate antibody (αCD44). First, O2LNCs are formed by a core of olive oil surrounded by a shell containing phospholipids, a nonionic surfactant, and deoxycholic acid molecules. Then, O2LNCs were coated with an αCD44 antibody (αCD44-O2LNC). The optimization of an αCD44 coating procedure, a complete physicochemical characterization, as well as clear evidence of their efficacy in vitro and in vivo were demonstrated. Our results indicate the high targeted uptake of these αCD44-O2LNCs, and the increased antitumor efficacy (up to four times) of paclitaxel-loaded-αCD44-O2LNC compared to free paclitaxel in pancreatic CSCs (PCSCs). Also, αCD44-O2LNCs were able to selectively target PCSCs in an orthotopic xenotransplant in vivo model.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC-ND).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.